Human chorionic gonadotropin attenuates amyloid-β plaques induced by streptozotocin in the rat brain by affecting cytochrome c-ir neuron density

Emsehgl Nikmahzar 1, Mehrdad Jahanshahi 2*, Leila Elyasi 2, Mohsen Saeidi 3, Fatemeh Babakordi 1, Gozal Bahlakeh 1

1 Neuroscience Research Center, Golestan University of Medical Sciences, Gorgan, Iran
2 Neuroscience Research Center, Department of Anatomy, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran
3 Stem Cell Research Center, Department of Immunology, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

ABSTRACT

Objective(s): Amyloid β plaques, in Alzheimer’s disease, are deposits in different areas of the brain such as prefrontal cortex, molecular layer of the cerebellum, and the hippocampal formation. Amyloid β aggregates lead to the release of cytochrome c and finally neuronal cell death in brain tissue. hCG has critical roles in brain development, neuron differentiation, and function. Therefore, we investigated the effect of hCG on the density of the congophilic Aβ plaque and cytochrome c-ir neurons in the hippocampus, prefrontal cortex, and cerebellum of Streptozotocin (STZ)-treated rats.

Materials and Methods: Alzheimer model in rats (except the control group) was induced by streptozotocin (3 mg/kg, Intracerebroventricularly (ICV)). Experimental group rats received streptozotocin and then different doses of hCG (50, 100, and 200 IU, intraperitoneally) for 3 days. 48 hr after last drug injection and after histological processing, the brain sections were stained by congo red for congophilic amyloid β plaques and cytochrome c in the hippocampus, prefrontal cortex, and cerebellum were immunohistochemically stained.

Results: Density of congophilic Aβ plaques and cytochrome c-immunoreactive neurons was significantly higher in ICV STZ treated rats than controls. Treatment with three doses of hCG significantly decreased the density of congophilic Aβ plaques and cytochrome c-immunoreactive neurons in the rat hippocampus, prefrontal cortex, and cerebellum in ICV STZ-treated rats (P<0.05).

Conclusion: hCG can be useful in AD patients to prevent the congophilic Aβ plaque formation and decrease cytochrome c-immunoreactive neuron density in the brain.

Introduction

Alzheimer’s disease (AD) accompanies age and over 90 percent of these patients are first diagnosed after age 65 (1). AD causes a progressive loss of cognitive functions (2). Also, AD is becoming an epidemic as well as an economic problem worldwide (3). It is described by the presence of amyloid β (Aβ) plaques, neurofibrillary tangles, neuroinflammation, and oxidative stress (2-4).

AD starts in the hippocampus and entorhinal cortex and then affects other parts of the brain cortex (5) and the cerebellum (6, 7). Also in this disease, brain atrophy and ongoing loss of neurons is observed mainly in the frontal cortex, hippocampus, and limbic areas (8).

In AD, Aβ plaques deposit in the hippocampus, amygdala, insular, entorhinal and cingulate cortices, subcortical nuclei, brainstem structures, and the molecular layer of the cerebellum (9). Aβ becomes neurotoxic when it aggregates, and these aggregates lead to a synaptic dysfunction and neuronal cell death in the brain tissue (10-12). One of the important reasons of AD pathophysiology is mitochondrial damage in neurons (3). Additional, increase of Aβ peptide leads to dysfunctioning of mitochondrial Ca2+ channels, opening of mitochondrial permeability transition pore (13), which enhances the release of proapoptotic proteins such as cytochrome c and apoptosis-inducing factor from the mitochondria (14, 15). Cytochrome c is a protein found in the inner membrane of the mitochondrion and it participates in the initiation of mitochondrial apoptotic pathways. Transfer of cytochrome c from mitochondria to the cytosol causes the activation of the caspase cascade (15). Hence, inhibition of Aβ accumulation or its effects may be a key solution to inhibit the initiation of AD or slow down its etiological progression (11).

Streptozotocin (STZ), a glucosamine-nitrosourea complex with beta-cytotoxic action, is widely used to prompt oxidative damage, damage glucose metabolism, apoptosis, and tau/Aβ pathology, finally leading to cognitive deficits in both in vivo and in vitro models of AD (1, 16-18).

Human chorionic gonadotropin (hCG) is a heterodimeric glycoprotein hormone that binds to the G-protein-coupled receptor often called luteinizing hormone (LH)/hCG receptor (19). LH and hCG have a similar structure and share the same receptor; LH/hCG receptor (20). LH/hCG have critical roles in brain development, neuron differentiation, and function (21). In the existence of highly purified hCG, cultured
rat neurons have been shown to respond in a dose-dependent manner by growing the neuritic processes and total cellular protein and by decreasing apoptosis (21). hCG has protective effects against oxidative stress through inhibition of apoptosis, activation of cell survival signaling, and keeping mitochondrial function (22). A previous study reported increases in brain Aβ levels after administration of hCG in female rats (23). But in another study on a mouse model of AD, Barron et al. (24) showed that treatment by hCG did not change Aβ42 levels. Further, ablation of LH decreases Aβ deposition in Alzheimer amyloid protein precursor (APP) transgenic mice (25). So, the effects of hCG on Aβ levels are contradictory and also, the effects of this hormone on the formation of Aβ plaques and density of cytochrome c-immunoreactive (ir) neurons in Intracerebroventricular (ICV)-STZ rat model of AD is not fully understood. Therefore, we investigated the effect of administration of hCG on the density of congophilic Aβ plaque and cytochrome c-ir neurons in the hippocampus, prefrontal cortex, and cerebellum of STZ-treated rats.

Materials and Methods

Animals

The experimental protocol was conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 8023, revised 1978) and all procedures had the approval of the Ethics Committee of Golestan University of Medical Sciences, Gorgan, Iran. The present study was performed on forty Wistar adult male rats weighing 180–220 g (Pasteur Institute, Tehran, Iran), randomly divided into five groups (eight rats in each group). The rats were maintained under a 12-hr light/dark cycle at 22±3 °C while food and water were available ad libitum.

ICV injection of streptozotocin

Adult male Wistar rats were anesthetized with a mixture of ketamine and xylazine (IP) and placed in a stereotaxic apparatus (David Kopf Instruments, USA). The stereotaxic coordinates for lateral ventricles were −0.8 mm posterior to the bregma, ±1.5 mm lateral, and −4.2 mm deep from the dural surface (26). Under sterile conditions and anesthesia, 21-gauge guide cannulae were implanted in the right and left lateral ventricles. Cannulae were secured with dental cement and acrylate to the skull. Afterward, 27-gauge stainless steel stylets were inserted into the guide cannulae to keep patency prior to microinfusions. The skin was closed with single stitches. Next, the rats were placed in single cages and were permitted to recover for at least 7 days (27, 28). STZ (Sigma, USA) ICV microinjections at a dose of 3 mg/kg in saline (5 μl/injection site) were done on days one and three of the experiment (29) using a 27-gauge injection needle connected to a Hamilton microsyringe (10 μl) by polyethylene tubing.

Drug administration

Rats were randomly divided into five groups (eight rats per group) as follows: control, sham (STZ + Saline) and three experimental (STZ+hCG) groups (eight rats per group). Control group rats were the intact group (without surgery and no drug injection). Rats in sham and experimental groups first received ICV injections of STZ (on days one and three of the experiment). Then, 6 days after last ICV injection of STZ, these rats (except the control group) received IP injections of the vehicle (saline, 200 μl) and/or hCG (Darou Pakhsh Pharmaceutical Mfg Co, Iran) with three doses of 50, 100, and 200 IU/200 μl saline (30), for 3 days. The IP injections of hCG and/or saline were given at 9:00 AM.

Histological examination

Tissue preparation: Forty-eight hr after the last drug injection, the brain tissue was removed by decapitation in deep anesthesia and the brain tissues were fixed in 4% paraformaldehyde for 7 days. Histological processing was done with an automated tissue processing machine (Did Sabz, Urmia, Iran) (31). Serial 6-μm sagittal slices were collected from the hippocampus, prefrontal cortex, and cerebellum (26). Finally, the brain slices were distributed into two sets for different staining separately.

Congo red staining

For detection of Aβ plaque deposits in the brain tissue, the brain sections were stained with Congo red (Tek-Path, Turkey) (32, 33). Deparaffinized and hydrated brain sections were incubated with 1% Congo red solution at 56 °C for 45 min. After being washed in saturated aqueous lithium carbonate for 15 sec, slides were stained with Mayer’s hematoxylin solution for 1 min. Then, the slides were dehydrated in 96% and 100% ethanol and cleared in xylene for 3-4 min and coverslipped with Entellan (Merck, Germany) (Figure 1).

Immunohistochemical staining

Cytochrome c-ir neurons were evaluated by immunohistochemical staining in the rat hippocampus, prefrontal cortex, and cerebellum according to our previous study (28). Briefly, after deparaffinization and rehydration, retrieval solution (pH=9, Tashkis Baft Aragen, Iran) was used for antigen retrieval at 90–95 °C for 20 min, the slides were allowed to cool at room temperature and then washed with washing buffer (PBS/ Tween 20 in 0.1 % Triton X-100). The activity of endogenous peroxidase was blocked by incubating the brain sections in 0.3% hydrogen peroxide solution in PBS for 10 min at room temperature and washed.
in washing buffer. For 20 min at room temperature, the sections were blocked with avidin/biotin blocking solution (Dako, Denmark) and then rinsed with washing buffer. Nonspecific reactivity was blocked by adding 1% bovine serum albumin intended for 60 min at 37 °C. Next, the brain sections were incubated with anti-cytochrome c Rabbit polyclonal antibody (1:100, Abcam Inc., USA) for 60 min at 37 °C and rinsed with washing buffer. The secondary antibody was biotinylated goat anti-rabbit IgG (ready to use, Abcam Inc., USA) which was applied to the sections for 60 min at 37 °C and then rinsed with the washing buffer. The brain sections were then incubated with streptavidin-HRP protein (1:5000, Abcam Inc., USA) for 30 min at room temperature, and the brain sections rinsed with washing buffer. Specific labeling was visualized using DAB (Dako, Denmark) as chromogen and Meyer's Hematoxylin was used to stain the background by applying it lightly on the sections for 3–4 sec. To finish, the brain sections were dehydrated in ethanol, cleared in xylene, and mounted with Entellan glue (Merck, Germany) (Figure 2).

Image processing and cell counting

Images were captured by an Olympus DP73 digital camera (Japan) equipped with an Olympus BX 53 light microscope (Japan) at a 40× magnification for prefrontal cortex and hippocampal CA1, CA3, and DG areas, at a 100× magnification for the cerebellum. Cytochrome c-ir neurons and congophilic Aβ plaques were counted in a 30000 μm² area at the II / III layers of the prefrontal cortex (34) and in pyramidal layers of CA1 and CA3 areas of the hippocampus and also in the granular layer of hippocampal DG area (27, 28, 35, 36). In the cerebellum, congophilic Aβ plaques were counted in a 30000 μm² at the molecular layer of the cerebellum (37-39) and cytochrome c-ir neurons in a 4800 μm² at the granular layer of the cerebellum. All counting for cytochrome c-ir neurons and congophilic Aβ plaques were done by the ImageJ software and imaging and counting were performed blind to treatment.

Statistical analysis

Statistical evaluations were carried out using One-way analysis of variance (ANOVA) with post hoc LSD test via SPSS software v.16 (Armonk, NY, USA). For all comparisons, the data are presented as means±SD. P<0.05 was considered significant.

Results

hCG effect on congophilic Aβ plaque density in brains of ICV STZ-treated rats

One-way ANOVA analysis and LSD post hoc test demonstrated that density of congophilic Aβ plaques in CA1, CA3, and DG areas of the hippocampus were significantly higher in the STZ+Saline group compared with the control group (P<0.001; Figures 3A–C).

There was significant difference of congophilic Aβ plaque density in the prefrontal cortex between STZ+Saline and control groups (P<0.001; Figures 3D, E).

Also, the difference of congophilic Aβ plaque density in the cerebellum between STZ+Saline and control
The concentration of Aβ plaque decreased in all hippocampal sub-regions. These differences were significant as compared with the STZ+Saline group (P<0.001; Figures 3A–C).

In CA1, CA3, and DG sub-regions of the hippocampus, administration of hCG with 100 and 200 IU could significantly decrease the congophilic Aβ plaque density as compared with the STZ+50 IU hCG group (P<0.001; Figures 3A, B).

Also, in CA1 and CA3 areas of the hippocampus, the congophilic Aβ plaque density was significantly different between STZ+100 IU hCG and STZ+200 IU hCG groups (P<0.001 and P<0.01, respectively; Figures 3A, B).

There was significant decrease in congophilic Aβ plaque density as compared with the STZ-saline group in the cerebellum and prefrontal cortex after administration of hCG with three doses (P<0.001; Figures 3D, E). But in the cerebellum and prefrontal cortex, after treatment with hCG at doses of 50, 100, and 200 IU, significant differences between those groups was not observed.

hCG effect on the density of cytochrome c-ir neurons in brains of ICV STZ-treated rats

Tables 1 and 2 show that in the STZ+Saline group, ICV injection of STZ significantly increased the number of cytochrome c-ir neurons in comparison with the control group in all areas of the hippocampus, prefrontal cortex, and cerebellum (P<0.001; Tables 1, 2). Treatment with hCG (doses 50, 100, and 200 IU, IP) for three days significantly decreased cytochrome c-ir neuron density in all areas of hippocampal formation in comparison to the STZ+Saline group (P<0.001; Table 1).

In CA1 area of the hippocampus, injection of 100 IU hCG could significantly decrease cytochrome c-ir neuron density in comparison with the STZ+50 IU hCG group (P<0.01; Table 1). Also in this area, significant difference was observed between STZ+100 IU hCG and STZ+200 IU hCG groups in cytochrome c-ir neuron density (P<0.05; Table 1).

In CA1 and CA3 areas of the hippocampus, cytochrome c-ir neuron density in the STZ+200 IU hCG group was statistically lower compared with the STZ+50 IU hCG group (P<0.001 and P<0.05, respectively; Table 1).

In DG area of the hippocampus, there was no significant difference between the hCG-treated groups in cytochrome c-ir neuron density.

Also, hCG administration at doses of 50, 100, and 200 IU (IP, for three days) decreased the density of cytochrome c-ir neurons in the prefrontal cortex and cerebellum.

Discussion

Administration of hCG (50, 100, and 200 IU) to STZ-treated rats significantly decreased the density of congophilic Aβ plaques and cytochrome c-ir neurons in the hippocampus, cerebellum, and prefrontal cortex of rat brains. These effects were dose-dependent, so we found most effects in the high dose of hCG.

Extracellular amyloid plaques are one of the major histopathological hallmarks of AD (40), and mostly deposited in the brain cortex, in the hippocampus (2), in the molecular layer of the cerebellum, and rarely in the granule cell layer of the cerebellum (37, 38). Many features of AD were observed following ICV injections of STZ in rodents (41, 42), such as accumulation of Aβ (41, 43) in the hippocampus (42, 44). We also found an accumulation of congophilic Aβ plaques in the hippocampus, prefrontal cortex, and cerebellum after ICV injections of STZ.

Some previous studies showed that hCG administration leads to an increase in Aβ40 accumulation in a mouse model of AD (23, 24, 45). But Barron et al. reported that levels of Aβ42 did not change with hCG treatment in a mouse model of AD (24), while administration of hCG to ovariectomized rats increased soluble Ab1-40 and Ab1-42.
42 levels (23). Indeed, hCG promotes the amyloidogenic pathway of APP metabolism in which Aβ is formed (45, 46). Also, adding of hCG to human embryonic stem cells can cause increased expression in all forms of Aβ precursor protein (47), while SHSY5Y neuroblastoma cells increased β-cleavage of the amyloid precursor protein when treated to high levels of hCG (45). Several studies have reported that LH ablation and also genetic ablation of the LH receptor can lead to reduction of Aβ plaques in the hippocampus and cerebral cortex in a mouse model of AD (25, 48).

It is documented that mitochondria play a major role in the regulation of cell death, particularly cell apoptosis and mitochondrial dysfunction are symbols of Aβ-induced toxicity of neurons in AD (49). The mitochondria-mediated cell death was evaluated by measuring the release of cytochrome c into the cytosol and following activation of caspase-3 (50). Indeed, the release of cytochrome c is the first step in an apoptotic pathway (51, 52). Also, STZ-ICV administration in rats induces mitochondrial abnormalities in rat brains (44). It is reported that STZ exposure of cultured neurons can cause significant disturbance of glucose uptake and mitochondrial function that then results in mitochondrial membrane potential damage, excessive calcium overload (53), translocation of cytochrome c in the cytosol, increased appearance of caspase-3, DNA damage, and finally neuronal death (54). Our data indicated that ICV injection of STZ to rats causes increased cytochrome c-ir neuron density in the brain.

It seems release of cytochrome c from mitochondria to the cytosol can increase by STZ-induced Aβ deposition. Indeed, Aβ can induce mitochondrial dysfunction and also lead to the release of cytochrome c (55, 56); an apoptosome is formed and it activates the executioner caspase-9, which in turn activates the executioner caspases-3, and finally results in apoptosis (57, 58). In our present study, ICV injection of STZ to rats increased the density of congophilic Aβ plaques and cytochrome c-ir neurons in the hippocampus, prefrontal cortex, and cerebellum, this increase was statistically significant.

Indeed, it was reported that treatment with hCG can stimulate the proliferation of cultured human ovarian surface epithelium cells, and it can inhibit the apoptosis of these cells induced by serum deprivation. The signaling of LH/hCG followed by up-regulation of insulin-like growth factor-1 is presumably elaborated in the inhibition of apoptosis of human ovarian surface epithelium cells (59). Also, the proliferation of endogenous neural stem cells is promoted by hCG (60). The previous results indicated that gonadotropins, such as hCG, have the potential to induce cell proliferation and protect from cell death in vitro (61, 62). Likewise, by pretreatment with hCG, cytochrome c, p-Bax, p-caspase 9, and caspase 3 activation was decreased in comparison with that found in the absence of hCG. Moreover, these effects were accompanied by raised activation of extracellular-signal-regulated kinases 1/2 and Akt (22).

In summary, we found that treatment with hCG can decrease the rise in density of congophilic Aβ plaques and cytochrome c-ir neurons in rat brains. These results showed that the protective effect of hCG in attenuating STZ-induced congophilic Aβ plaques can increase through reduction of cytochrome c-ir neuron density.

Conclusion

We concluded that hCG can be useful for the treatment of dementia and Alzheimer’s disease by preventing the formation of congophilic Aβ plaques and decreasing cytochrome c-ir neuron density in the brain of AD patients. It seems hCG can decrease the congophilic Aβ plaque formation by decreasing cytochrome c-ir neuron density in the IVC STZ-treated rat brains.

Acknowledgment

This work was financially supported by the Research Affairs of Golestan University of Medical Sciences, Gorgan, Iran. The authors would like to thank the Neuroscience Research Center, Gorgan, Iran, for histological experiments.

Conflicts of Interest

All authors declare that there are no conflicts of interest.

References

1. Guo XD, Sun GL, Zhou TT, Xu X, Zhu ZY, Rukachaisirikul V, et al. Small molecule LX2343 ameliorates cognitive deficits in AD model mice by targeting both amyloid β production and clearance. Acta Pharmacol Sin 2016; 37:1281-1297.
2. Comes G, Manso Y, Escrig A, Fernandez-Gayol O, Sanchis P, Molinero A, et al. Influence of transgenic metallocathionein-1 on gliosis, CA1 neuronal loss, and brain metal levels of the Tg2576 mouse model of Alzheimer’s disease. Int J Mol Sci 2017; 18:251.
3. Islam MA, Khandker SS, Alam F, Khalil MI, Kamal MA, Gan SH. Alzheimer’s disease and natural products: future regimens emerging from nature. Curr Top Med Chem 2017; 17:1408-1428.
4. Golpich M, Amini E, Mohamed Z, Azman Ali R, Mohamed Ibrahim N, Ahmadiani A. Mitochondrial dysfunction and biogenesis in neurodegenerative diseases: Pathogenesis and treatment. CNS Neurosci Ther 2017; 23:5-22.
5. Cardoso S, Carvalho C, Correia SC, Seiça RM, Moreira PL. Alzheimer’s disease: From mitochondrial perturbations to mitochondrial medicine. Brain Pathol 2016; 26:632-647.
6. Thomann PA, Schläfer C, Seidl U, Dos Santos V, Essig M, Schröder J. The cerebellum in mild cognitive impairment and Alzheimer’s disease—a structural MRI study. J Psychiatr Res 2008; 42:1198-1202.
7. Mavroudis IA, Fotiou DF, Adipepe LF, Manani MG, Njau SD, Psaroulis D, et al. Morphological changes of the human purkinje cells and deposition of neuritic plaques and neurofibrillary tangles on the cerebellar cortex of Alzheimer’s disease. Am J Alzheimers Dis Other Dement 2010; 25:585-591.
8. Venkatadheppa C, Harish G, Mahadevan A, Bharath MS, Shankar SK. Elevated oxidative stress and decreased antioxidant function in the human hippocampus and frontal cortex with increasing age: implications for neurodegeneration in Alzheimer’s disease. Neurochem Res 2012; 37:1601-1614.
9. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1:a006189.
10. Arendt T. Synaptic degeneration in Alzheimer’s disease. Spring Harb Perspect Med 2011; 1:a006189.
11. Han SH, Park JC, Mook-Jung I. Amyloid β-interacting proteins as therapeutic targets for Alzheimer’s disease. Acta Neuropathol 2009; 118:167-179.
partners in Alzheimer’s disease: From accomplices to possible therapeutic targets. Prog Neurobiol 2016; 137:17-38.
12. Wang Y, Cai B, Shao J, Wang TT, Cai RZ, Ma CJ, et al. Genistein suppresses the mitochondrial apoptotic pathway in hippocampal neurons in rats with Alzheimer’s disease. Neural Regen Res 2016; 11:1153–1158.
13. Calkins MJ, Manczak M, Mao P, Shirendub U, Reddy PH. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Genet 2011; 20:4515-4529.
14. Carvalho C, Correa SC, Perry G, Castellani RJ, Moreira PL. Cerebrovascular and mitochondrial abnormalities in Alzheimer’s disease: A brief overview. J Neural Transm (Vienna) 2016; 123:107-111.
15. Kerr JS, Adriaanse BA, Greig NH, Mattson MP, Cader MZ, Bohr VA, et al. Mitophagy and Alzheimer’s disease: cellular and molecular mechanisms. Trends Neurosci 2017; 40:151-166.
16. Sodhi RK, Singh N. All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer’s type. Prog Neuropsychopharmacol Biol Psychiatry 2013; 40:38-46.
17. Kumat PK, Kalani A, Rai S, Tota SK, Kumar A, Ahmad AS. Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: A therapeutic intervention for treatment of sporadic Alzheimer’s disease (sAD)-like pathology. Mol Neurobiol 2016; 53:4548-4562.
18. Souza LC, Jêsse CR, de Gomes MG, Viana CE, Mattos E, Silva NC, et al. Intracerebroventricular administration of streptozotocin as an experimental approach to depression: Evidence for the involvement of proinflammatory cytokines and indoleamine-2, 3-dioxygenase. Neurotox Res 2017; 31:464-477.
19. Lin Y, Kardos J, lmai M, Ikenoue T, Kinoshita M, Sugiki T, et al. Amorphous aggregation of cytochrome c with inherently low amyloidogenicity is characterized by the metastability of supersaturation and the phase diagram. Langmuir 2016; 32:2010-2022.
20. Kunal SB, Killivalavan A, Medhamurthy R. Involvement of Src family of kinases and cAMP phosphodiesterase in the luteinizing hormone/chorionic gonadotropin receptor-mediated signaling in the corpus luteum of monkey. Reprod Biol Endocrinol 2012; 10:25.
21. Meethal SV, Smith MA, Bowen RL, Atwood CS. The gonadotropin connection in Alzheimer’s disease. Endocrine 2005; 26:317-326.
22. Surico D, Farruggio S, Marotta P, Raina G, Mary D, Surico N, et al. Human chorionic gonadotropin protects vascular endothelial cells from oxidative stress by apoptosis inhibition, cell survival signalling activation and mitochondrial function protection. Cell Physiol Biochem 2015; 36:2108-2120.
23. Berry A, Tomidokoro Y, Ghiso J, Thornton J. Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-β levels in female rats. Horm Behav 2008; 54:143-152.
24. Barron AM, Verdile G, Taddei K, Bates KA, Martins RN. Effect of chronic hCG administration on Alzheimer’s-related cognition and Aβ accumulation in PS1KI mice. Endocrinology 2010; 151:5380-5388.
25. Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, et al. Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 2006; 1762:447-452.
26. Paxinos G, Watson C. The rat brain in stereotaxic coordinates: San Diego: Academic Press; 2007.
27. Moghadami S, Jahanshahi M, Sepehri H, Amini H. Gonadectomy reduces the density of androgen receptor-immunoreactive neurons in male rat’s hippocampus: testosterone replacement compensates it. Behav Brain Funct 2016; 12:5-14.
28. Jahanshahi M, Nikmahzar E, Elyasi L, Babakordi F, Hooshmand E. a2-Adrenoceptor-ir neurons’ density changes after single dose of clonidine and yohimbine administration in the hippocampus of male rats. Int J Neurosci 2018; 128:404-411.
29. Weerateerangkul P, Praputpittaya C, Banjerdpochai R. Effects of Ascorbic acid on streptozotocin-induced oxidative stress and memory impairment in rats. Thai J Physiol Sci 2008; 20:54-61.
30. Lukacs H, Hiatt E, Lei Z, Rao CV. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cycling female rats. Horm Behav 1999; 35:42-58.
31. Jahanshahi M, Nikmahzar E, Babakordi F. The effect of Ginkgo biloba extract on scopolamine-induced apopitosis in the hippocampus of rats. Anat Sci Int 2013; 88:217-222.
32. Wikcock DM, Gordon MN, Morgan D. Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nat Protoc 2006; 1:1591-1595.
33. Kumar A, Singh N. Calcineurin inhibitors improve memory loss and neuropathological changes in mouse model of dementia. Pharmacol Biochem Behav 2017; 153:147-159.
34. Palkovits M, Šebeková K, Klenovics KS, Kebis A, Fazeli G, Bahner U, et al. Neuronal activation in the central nervous system of rats in the initial stage of chronic kidney disease-modulatory effects of losartan and moxonidine. PloS One 2013; 8:e66543.
35. Jahanshahi M, Sadeghi Y, Hosseini A. Estimation of astrocyte number in different subfield of rat hippocampus. Pak J Biol Sci 2006; 9:1595-1597.
36. Seifhosseini S, Jahanshahi M, Moghimi A, Aazami N-S. The effect of scopolamine on avoidance memory and hippocampal neurons in male Wistar rats. Basic Clin Neurosci 2011; 3:9-15.
37. Kusbeci OY, Bas O, Gocmen-Mas N, Karabekir HS, Yucel A, Ertekin T, et al. Evaluation of cerebellar asymmetry in Alzheimer’s disease: a stereological study. Dement Geriatr Cogn Disord 2009; 28:1-5.
38. Chen J, Cohen ML, Lerner AJ, Yang Y, Herrup K. DNA damage and cell cycle events implicate cerebellar dentate nucleus neurons as targets of Alzheimer’s disease. Mol Neurodegener 2010; 5:60.
39. Jahanshahi M, Sadeghi Y, Hosseini A, Naghdi N, Golalipour MJ. Astrocytes in Molecular Layer of Cerebellum after Spatial Learning. Basic Clin Neurosci 2012; 3:16-21.
40. Li M, Chen L, Lee DHS, Yu LC, Zhang Y. The role of intracellular amyloid β in Alzheimer’s disease. Prog Neurobiol 2007; 83:131-139.
41. Knezovic A, Osmanovic-Barlar J, Curlin M, Hof PR, Simic G, Riederer P, et al. Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease. J Neural Transm (Vienna) 2015; 122:577-592.
42. Ravelli KG, dos Anjos Rosário B, Camarini R, Hernandez MS, Britto LR. Intracerebroventricular streptozotocin as a model of Alzheimer’s disease: Neurochemical and behavioral characterization in mice. Neurotox Res 2017; 31:327-333.
43. Salkovic-Petrisic M, Osmanovic-Barlar J, Brückner MK,
Hoyer S, Arendt T, Riederer P. Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study. J Neural Transm (Vienna) 2011; 118:765-772.

44. Correia SC, Santos RX, Santos MS, Casadesus G, LaManna JC, Perry G, et al. Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer’s disease. Curr Alzheimer Res 2013; 10:406-419.

45. Saberi S, Du YP, Christie M, Goldsberry C. Human chorionic gonadotropin increases β-cleavage of amyloid precursor protein in SH-SY5Y cells. Cell Mol Neurobiol 2013; 33:747-751.

46. Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, et al. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-β precursor protein and amyloid-β deposition. J Biol Chem 2004; 279:20539-20545.

47. Porayette P, Gallego MJ, Kaltcheva MM, Meethal SV, Atwood CS. Amyloid-β precursor protein expression and modulation in human embryonic stem cells: A novel role for human chorionic gonadotropin. Biochem Biophys Res Commun 2007; 364:522-527.

48. Lin J, Li X, Yuan F, Lin L, Cook CL, Rao CV, et al. Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 2010; 69:253-261.

49. Tan JW, Kim MK. Neuroprotective effects of Biochanin A against β-amyloid-induced neurotoxicity in PC12 cells via a mitochondrial-dependent apoptosis pathway. Molecules 2016; 21:548.

50. Bras M, Queenan B, Susin SA. Programmed cell death via mitochondria: different modes of dying. Biochemistry (Moscow) 2005; 70:231-239.

51. Nicholls DG, Budd SL. Mitochondria and neuronal survival. Physiol Rev 2008; 80:315-360.

52. Koo JH, Kang EB, Oh YS, Yang DS, Cho JY. Treadmill exercise decreases amyloid-β burden possibly via activation of SIRT-1 signaling in a mouse model of Alzheimer’s disease. Exp Neurol 2017; 288:142-152.

53. Genrikhs EE, Stelmashook EV, Golyshova VA, Aleksandrova OP, Isaev NK. Streptozotocin causes neurotoxic effect in cultured cerebellar granule neurons. Brain Res Bull 2017; 130:90-94.

54. Biswas J, Goswami P, Gupta S, Joshi N, Nath C, Singh S. Streptozotocin induced neurotoxicity involves Alzheimer’s related pathological markers: A study on N2A cells. Mol Neurobiol 2016; 53:2794-2806.

55. Wang Y, Miao Y, Mir AZ, Cheng L, Wang L, Zhao L, et al. Inhibition of beta-amyloid-induced neurotoxicity by pinocembrin through Nrf2/HO-1 pathway in SH-SY5Y cells. J Neurol Sci 2016; 368:223-230.

56. An HM, Lin C, Gu C, Chen JJ, Sun WX, Jin M, et al. Di-Huang-Yi-Zhi herbal formula attenuates amyloid-β-induced neurotoxicity in PC12 cells. Exp Ther Med 2017; 13:3003-3008.

57. Wang X, Su B, Perry G, Smith MA, Zhu X. Insights into amyloid-β-induced mitochondrial dysfunction in Alzheimer disease. Free Radic Biol Med 2007; 43:1569-1573.

58. Yankner BA, Lu T. Amyloid-β-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 2009; 284:4755-4759.

59. Kuroda H, Mandai M, Konishi I, Tsuruta Y, Kusakari T, Kariya M, et al. Human ovarian surface epithelial (OSE) cells express LH/hCG receptors, and HCG inhibits apoptosis of OSE cells via up-regulation of insulin-like growth factor-1. Int J Cancer 2010; 91:309-315.

60. Belayev L, Khoutorova L, Zhao KL, Davidoff AW, Moore AF, Cramer SC. A novel neurotrophic therapeutic strategy for experimental stroke. Brain Res 2009; 1280:117-123.

61. Edmondson RJ, Monaghan JM, Davies BR. Gonadotropins mediate DNA synthesis and protection from spontaneous cell death in human ovarian surface epithelium. Int J Gynecol Cancer 2006; 16:171-177.

62. Elzarrad K, Haroon A, Reed D, Al-Mehdi AB. Early incorporated endothelial cells as origin of metastatic tumor vascularogenesis. Clin Exp Metastasis 2009; 26:589-598.